These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3656356)

  • 41. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
    Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
    J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacological, hematological, and physiological effects of a new thromboxane synthetase inhibitor (CGS-13080) during cardiopulmonary bypass in dogs.
    DeCampli WM; Goodwin D; Kosek JC; Handen CE; Mitchell RS; Miller DC
    Ann Thorac Surg; 1986 Dec; 42(6):690-6. PubMed ID: 3789860
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of DP-1904, a new thromboxane A2 synthetase inhibitor, on guinea pig experimental asthma.
    Takami M; Takata Y; Matsumoto K; Ono S; Tsukada W
    Ann N Y Acad Sci; 1991; 629():407-9. PubMed ID: 1952565
    [No Abstract]   [Full Text] [Related]  

  • 44. Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives and related compounds.
    Takeuchi K; Kohn TJ; True TA; Mais DE; Wikel JH; Utterback BG; Wyss VL; Jakubowski JA
    J Med Chem; 1998 Dec; 41(27):5362-74. PubMed ID: 9876106
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Production of platelet thromboxane A2 inactivates purified human platelet thromboxane synthase.
    Hall ER; Tuan WM; Venton DL
    Biochem J; 1986 Feb; 233(3):637-41. PubMed ID: 3707514
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Studies on the thromboxane synthesizing system in human platelet microsomes.
    Tai HH; Yuan B
    Biochim Biophys Acta; 1978 Dec; 531(3):286-94. PubMed ID: 737191
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
    Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M
    Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor.
    Chiabrando C; Broggini M; Castelli MG; Cozzi E; Castagnoli MN; Donelli MG; Garattini S; Giavazzi R; Fanelli R
    Cancer Res; 1987 Feb; 47(4):988-91. PubMed ID: 3100032
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
    J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mediation of bradykinin-induced contraction in canine veins via thromboxane/prostaglandin endoperoxide receptor activation.
    Aksoy MO; Harakal C; Smith JB; Stewart GJ; Zerweck CR
    Br J Pharmacol; 1990 Mar; 99(3):461-6. PubMed ID: 2110015
    [TBL] [Abstract][Full Text] [Related]  

  • 51. "Suicide" inactivation of thromboxane A2 synthase. Characteristics of mechanism-based inactivation with isolated enzyme and intact platelets.
    Jones DA; Fitzpatrick FA
    J Biol Chem; 1990 Nov; 265(33):20166-71. PubMed ID: 2243085
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design of an antithrombotic-antihypertensive agent (Wy 27569). Synthesis and evaluation of a series of 2-heteroaryl-substituted dihydropyridines.
    Archibald JL; Bradley G; Opalko A; Ward TJ; White JC; Ennis C; Shepperson NB
    J Med Chem; 1990 Feb; 33(2):646-52. PubMed ID: 2299629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CGS 15435A, a thromboxane synthetase inhibitor with an extended duration of action: a comparison with dazoxiben.
    Olson RW; Cohen DS; Ku EC; Kimble EF; Renfroe HB; Smith EF
    Eur J Pharmacol; 1987 Jan; 133(3):265-73. PubMed ID: 3104066
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of a thromboxane synthetase inhibitor, dazoxiben, during haemodialysis.
    Dodd NJ; Gordge MP; Weston MJ
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):67S-70S. PubMed ID: 6337605
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selective and nonselective inhibition of thromboxane formation.
    FitzGerald GA; Oates JA
    Clin Pharmacol Ther; 1984 May; 35(5):633-40. PubMed ID: 6370554
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition--I. Synthesis, structure-activity relationship, and evaluation of substituted omega-phenyl-omega-(3-pyridyl)alkenoic acids.
    Takeuchi K; Happ AM; Mais DE; Layman N; Utterback BG; Wyss VL; Jakubowski JA
    Bioorg Med Chem; 1994 Aug; 2(8):743-55. PubMed ID: 7894968
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 5. Synthesis and evaluation of enantiomers of 8-[[(4-chlorophenyl)sulfonyl]amino]-4-(3-pyridinylalkyl)octanoic acid.
    Bhagwat SS; Gude C; Cohen DS; Dotson R; Mathis J; Lee W; Furness P
    J Med Chem; 1993 Jan; 36(2):205-10. PubMed ID: 8423593
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904.
    Yoshida T; Ichikawa Y; Tojo T; Homma M
    Lupus; 1996 Apr; 5(2):129-38. PubMed ID: 8743126
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of Y-20811, a thromboxane A2 synthetase inhibitor, on experimentally induced coronary thrombosis in anesthetized dogs.
    Matsumoto Y; Ochi H; Aihara K; Inui J; Ikegami K
    Eur J Pharmacol; 1992 Mar; 213(2):167-70. PubMed ID: 1521557
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Specific binding of the thromboxane A2 antagonist 13-azaprostanoic acid to human platelet membranes.
    Hung SC; Ghali NI; Venton DL; Le Breton GC
    Biochim Biophys Acta; 1983 Feb; 728(2):171-8. PubMed ID: 6219702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.